mesothelioma drug

Genentech Halts Avastin Approval Filing for Mesothelioma

In 2015, data was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from a Phase III French study that demonstrated improved survival rates for patients who received bevacizumab (Avastin® Genentech, Inc.) in addition to the standard chemotherapy regimen of pemetrexed/cisplatin.
The outcome of the study prompted the independent French cooperative group and Genentech […]


What Do You Know About Keytruda and Opdivo?

If you live In the United States where pharmaceutical companies advertise directly to consumers, in the last few years you’ve likely seen many ads for drugs whose unbranded names end in “mab.” Many of the advertised drugs are used to treat disorders such as rheumatoid arthritis, Crohn’s disease, psoriasis, asthma, Alzheimer’s disease, to mention a […]


BREAKING NEWS: Data Released from Anetumab Ravtansine Study

Last week, at the World Conference on Lung Cancer, Dr. Raffit Hassan presented promising data on a novel agent, anetumab ravtansine, also known as BAY 94-9343. Anetumab ravtansine is an antibody-drug conjugate directed against the target molecule mesothelin which is highly expressed on mesotheliomas.
“Anetumab ravtansine shows encouraging efficacy in patients with advanced mesothelioma which warrants […]